IRay
Sponsors
Oraya Therapeutics, Inc.
Conditions
AMDAge Related Macular DegenerationAge-Related Macular DegenerationAge-related Macular DegenerationEye DiseasesMacular DegenerationPolypoidal Chorodial VasculopathyRetinal Diseases
Phase 1
Phase 2
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
CompletedNCT01016873
Start: 2009-11-30End: 2014-04-30Updated: 2014-12-05
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT01521065
Start: 2012-09-30End: 2016-10-31Target: 500Updated: 2013-04-26
Unknown Phase
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
WithdrawnNCT01339949
Start: 2011-06-30End: 2014-10-31Updated: 2011-12-30
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
NCT01516294
Start: 2012-01-31End: 2014-03-31Target: 12Updated: 2012-11-01
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
NCT01521819
Start: 2012-08-31End: 2014-08-31Target: 12Updated: 2012-10-25